In-silico design of novel myocilin inhibitors for glaucoma therapy by Tang, Min et al.
Tang et al 
Trop J Pharm Res, October 2017; 16(10): 2527  
 
Tropical Journal of Pharmaceutical Research October 2017; 16 (10): 2527-2533 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v16i10.29 
Original Research Article 
 
 
In-silico design of novel myocilin inhibitors for glaucoma 
therapy 
 
Min Tang, Yang Fu, Ying Fan, Ming-Shui Fu, Zhi Zheng and Xun Xu* 
Department of Ophthalmology, Shanghai general Hospital of Nanjing Medical University, Shanghai 200080, China 
 
*For correspondence: Email: xuxun9012@hotmail.com; Tel: 0086-021-63240090; Fax: 0086-021-36126336 
 
Sent for review: 6 June 2016        Revised accepted: 22 September 2017 
 
Abstract 
Purpose: To explore newer computational approaches in the design of novel myocilin inhibitors for the 
treatment of glaucoma. 
Methods: An in-silico virtual screening technique based on simulation of molecular docking was utilised 
to design a novel myocilin inhibitors for the treatment of glaucoma. The designed novel molecules were 
theoretically evaluated to predict their pharmacokinetic properties and toxic effects. Lead molecules 
were screened out in virtual screening technique on the basis of low binding energies obtained in 
AutoDock based molecular docking simulation. 
Results: Out of ten top lead compounds screened, ZINC01729523 and ZINC04692015 were promising, 
having shown potent inhibition of myocilin, good pharmacokinetic properties and absence of any toxic 
effects.  
Conclusion: In-silico virtual screening of molecular libraries containing a large number of ligands is 
very useful for short-listing of potential lead molecules for further structure-based discovery of anti-
glaucoma-drugs. 
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Glaucoma is the loss of visual sensitivity and 
field because of optic neuropathy associated with 
damage to the optic nerve heads. Traditionally, 
glaucoma is diagnosed by increased intra-ocular 
pressure (IOP), which is a very crucial factor in 
its pathogenesis. The normal range of IOP in 
healthy individuals is 10 to 21 mmHg [1-3]. An 
increase in IOP above this range creates a 
pressure against the optic nerve, resulting in the 
death of the nerve cells. Increased IOP leads to 
improper draining of the aqueous humour 
produced by the chambers of the eye between 
the cornea and the lens [1-3]. Glaucoma is 
associated with mutations in myocilin. Studies 
have shown that alterations in the size, electrical 
charge and polarity of myocilin due changes in its 
peptide sequence are important for development 
of glaucoma [4-7]. 
 
According to the vasogenic theory, factors such 
as insufficient blood flow to retina due to 
increased perfusion pressure required in the eye, 
dysregulated perfusion, and vessel wall 
abnormalities damage the optic nerve by 
degeneration of axonal fibres of the retina [5-8]. 
Another theory suggests that the IOP may 
disrupt axoplasmic flow at the optic disk. Myocilin 
is produced by most ocular tissues such as iris, 
sclera, lens, cornea, retina ciliary body, optic 
nerves and trabecular meshwork (TM) [5-8]. 
Myocilin is present in the intracellular and 
extracellular portions of tissues. It is expressed in 
Tang et al 
Trop J Pharm Res, October 2017; 16(10): 2528  
 
TM cells which are responsible for the generation 
of resistance to out flow of aqueous humour; this 
resistance is accounts for the elevation of IOP 
and glaucoma [5-8]. World Health Organization 
(WHO) has reported that glaucoma is the second 
leading cause of blindness worldwide, and that 
about 70 million people across the age groups 
are affected by the disease. Multiple population-
based surveys estimated that about 79.6 million 
individuals would be affected by glaucoma by the 
year 2020 [8-10]. The increasing incidence of 
glaucoma across the world makes it expedient to 
develop a potent drug for its treatment.  
 
In the present study, in-silico approaches were 
applied to identify some myocilin inhibitors as 




All the molecular docking simulations were 
carried out utilizing Raccoon, AutoGrid4 and 
AutoDock4 software [11]. 
 
Selection and preparation of protein 
 
Human Myocilin Olfactomedin Domain protein 
bound to its endogenous ligand hexaethylene 
glycol (pdb id-4WXQ) was downloaded from 
RCSB protein data bank. The 4WXQ protein 
complex consists of a single polypeptide chain of 
277 amino acids [12]. The receptor protein 
myocilin was prepared for molecular docking by 
removing ligand and from active site, removal of 
water molecules which are not interacting with 
the ligand, and addition of polar hydrogen’s. The 
amino acid residues GLY252, LYS468, GLU253, 
TRP250, VAL251 and ARG470 are present in 
the active site of protein 4WXQ [12]. 
 
Selection of chemical libraries  
 
Diverse molecules (1880) present in the NCI 
“Diversity Set-II” molecular library were virtually 
screened to identify possible lead compounds. 
All the ligands used in virtual screening followed 
Lipinsky’s rule of five (ClogP< 5; H bond donor < 
5; H bond acceptor< 10; molecular weight< 500) 
for good pharmacokinetic properties [13-14]. 
 
Grid box formation 
 
Table 1 shows the grid box points of the three 
proteins. These were utilized for all docking runs. 
The grid box was placed in the center of the 
ligand to ensure that all the extended 
conformations of ligand fit into the grid box. 
 
Preparation of grid map  
 
The map files for different atom types in ligands 
and receptor viz. A, OA,C, HD, F, I, Br, Cl, N, 
NA, SA, S etc. were prepared by running 
Autogrid utility of the AutoDock suite. These map 
files were prepared by Autogrid and used by 
AutoDock for carrying out molecular docking 
simulations. 
 
Docking parameters  
 
Lamarckian genetic algorithm (LGA) is the 
primary conformational search approach in 
AutoDock [11]. In this search, a trail population is 
created for various possible conformations, and 
mutations and exchange of conformational 
parameters take place to compete in a similar 
manner to that of the successive generations for 
biological evolution by the selection of the final 
individuals with minimum binding energy. The 
‘‘Lamarckian’’ aspect is used for finding the local 
minima, and the local conformational space of 
the individual conformational search. These 
information’s are passed to later generations. 
Semi-empirical free energy force field is used to 
predict binding free energies of small molecules 
to macromolecular targets. The force field is 
based on a comprehensive thermodynamic 
model-based force field that allows incorporation 
of intra-molecular energies into the predicted 
binding free energy by evaluating energies for 
both the bound and unbound states. Docking 
parameter file was prepared for each ligand 
using the following conditions: number of GA 
runs was 150; maximum number of evaluations 
(short) was 250000; maximum number of 
generations was 27000; number of GA runs was 
10, and the rate of gene mutation was 0.02 
[13,14]. 
 
Validation of docking method  
 
The positions and orientations of the ligand 
obtained after the molecular docking study 
represented potential binding modes of the 
inhibitors. The various docking parameters 
considered in the docking methods were 
validated by re-docking individually crystallized 
hexaethyleneglycol (ligand) over Myocilin 
Olfactomedin Domain protein of Homo-sapiens. 
 
Table 1: Coordinates of grid box for the three proteins 
 
Proteins x-D y-D z-D Spacing (Ả) x center y center z center 
4WXQ 40 40 40 0.381 -2.133 -26.467 -21.434 
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The docked conformation of the bound ligand 
must perfectly overlap the crystallized chemical 
structure to obtain root mean square deviation 
(RMSD) values within acceptable range [11-14]. 
 
Virtual screening process 
 
The files necessary for performing virtual 
screening process were prepared by using the 
software Raccoon. Raccoon is a graphical user 
interface for AutoDock-based virtual screening of 
ligand libraries against a macromolecule. It is 
used to split molecular ligand library file having 
multiple number of ligands, to convert them into 
the pdbqt format required by AutoDock, and filter 
the unwanted ligands by using some common 
criteria, such as Lipinski's rules, fragment-like 
“rule of 3” and drug-likeness. Input file is 
validated at every step by evaluating the 
presence of non-standard atom types and 
ensuring that parameters, input filenames, and 
grid maps have coherent formats [13,14]. 
 
Analysis of results of docking simulation 
 
A script Summarize_results.py from Scripps 
Research Institute was utilized to sort the binding 
energies of the docked ligand and select the best 
hits. The results obtained from molecular docking 
simulation were evaluated on the basis of 
hydrophobic and polar interactions obtained 
between ligand and the binding residues present 
in the active ligand binding site of the 
macromolecule. The empirical range of the 
binding free energy should be in the range of -5 
to -15 Kcal/Mol. Binding affinities were calculated 
as in Eq 1. 
 
Ki = e[(ΔG/(RT)] ………………. (1) 
 
where ΔG=change in free energy upon binding, 
R=gas constant and T= absolute temperature 
[13]. 
 
Prediction of absorption, distribution, 
metabolism, excretion (ADME) and toxicity of 
lead compounds 
 
The toxic effects of the virtually-screened lead 
molecules were predicted by using the OSIRIS 
online program. The presence of major toxic 
effects such as mutagenicity, tumorigenicity, 
irritant effects and reproductive effects were 
predicted on the basis of functional groups 
present in the chemical structures of the lead 
compounds. This program also calculates drug-
likeness score and drug score of the lead 




Table 2 depicts the results of the internal 
validation for the proteins 1AM4 showing that the 
root mean square deviation (RMSD) value 
obtained conformed with the acceptable value of 
less than 1Å. This indicates that the docked 
conformation of the ligand has similar binding 
mode to that present in its bioactive 
conformation. In addition, a very good binding 
affinity value was obtained in internal validation 
of the molecular docking process. The binding 
residues involved in the binding of the ligand to 
the macromolecule are shown in Table 2. 
 
Figure 1 illustrates the binding mode and 
chemical interactions of the ligand hexa-ethylene 
glycol within the active binding site of human 
Myocilin Olfactomedin Domain protein, while 
Figure-2 shows the overlay of chemical 
structures of docked conformation of the ligand 
with respect to its crystallized bioactive 
conformation. Both the figures indicate that the 
docked conformation of the ligand has exactly 
the same binding mode and chemical 
interactions with the macromolecule as the 
bioactive conformation of the ligand. These 
results clearly suggest that the ligand binding 
mode obtained by molecular docking technique 
simulated exactly the binding mode observed 
within the human body. 
 
The potential ligands were selected by analysing 
the ligand-protein interactions for top-ranking 
pose of each ligand, and interactions of docked 
compound were visualized. Virtual screening 
results for human myocilin protein are 
enumerated in Table 3. Table 4 illustrates that all 
ten hits followed Lipinski’s rule of five [13-15]. 
 
The ligand-protein interactions in 4WQX were 
compared with the interactions of the shortlisted 
lead molecules. The best poses were identified 
using the following criteria in the given order of 
preference: lowest binding energy in the largest-
sized cluster, number of hydrogen bonds with 
active site residues and conservation of 
interactions with those from control docking. This 
was performed to ensure that the hits were 
actually docking exactly into the right binding site 
of interest. 
 
Two of the top ten screened lead molecules 
(ZINC01729523 and ZINC04692015) showed 
promising results on the bases of potent 
inhibition of myocilin, good pharmacokinetic 
properties, absence of toxic effects, as well as 
very good drug-likeness and acceptable Drug 
Score values. The ADME and toxicity results of 
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all the lead molecules obtained by virtual 
screening are shown in Figure 3. Some of the 
designed inhibitors showed poor 
pharmacokinetic profiles, high toxicity, 
mutagenicity, tumorogenicity and reproductive 
effects. 
 
Table 2: Internal validation results for the three proteins 
 







4WXQ GLY252, GLU253, 
TRP250 and VAL251 




Figure 1: Binding mode and chemical interactions of the ligand hexaethylene glycol within the active binding site 




Figure 2: Overlay of chemical structures of docked conformation of the ligand with respect to its crystallized 
bioactive conformation [12] 
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Table 3: Binding energies and affinities of five top hits from NCI “Diversity Set II” after virtual screening on 
Human Myocilin Olfactomedin domain protein 
 












































































Table 4: “Lipinski’s rule of five” for the hits on human myocilin protein 
 
Compound ID Mol. Wt. ClogP 2D PSA (Å2) HBA HBD 
ZINC01045090 374.45 6.06 58.18 5 0 
ZINC05180959 281.20 -0.18 97.03 10 2 
ZINC01729523 332.43 4.52 45.15 3 2 
ZINC04692015 464.37 -0.94 206.60 13 8 
ZINC01726776 348.42 7.06 52.83 3 0 
ZINC01834023 407.42 1.76 176.95 10 8 
ZINC01757986 294.28 0.63 102.58 9 3 
 
(ClogP = Calculated partition coefficient; Mol. Wt. = Molecular weight; 2D PSA = Two dimensional polar surface 
area; HBA = Hydrogen bond acceptor; and HBD = Hydrogen bond donor) 
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The amino acids, TRP250, VAL251, GLY252 and 
GLU253, are active binding residues present in 
the binding site for human Myocilin Olfactomedin 
Domain protein [12]. The identified binding 
residues involved in the binding of the ligand 
hexaethylene glycol is used for performing 
molecular docking simulation studies to identify 
novel ligand molecule with more binding affinity 
towards the receptor. Initially the molecular 
docking simulation process is validated by using 
re-docking of already bound ligand on the basis 
of its binding energy and overlay methods, which 
confirmed the similarity in binding patterns 
obtained by molecular docking simulation studies 
with that was occurring inside the human body 
[11]. 
 
After validating the molecular docking simulation 
technique, the similar parameters were utilised to 
perform molecular docking simulation based 
virtual screening by using ligand library “NCI 
Diversity Set-II” containing large number of 
diverse ligand molecules [13]. 
 
The results obtained in this study indicate that 
Autodock-based virtual screening is very 
beneficial in screening for the best binding lead 
molecules from the molecular library containing 
1880 diverse ligand molecules on the basis of 
their binding energies [11]. Two lead molecules 
ZINC01729523 and ZINC04692015, out of 
selected top seven lead molecules showed good 
pharmacokinetic properties, good drug likeness 
and Drug Score Values. In addition, they had no 




Molecular docking simulation-based in silico 
virtual screening using Autodock is very useful in 
short-listing potential lead compounds. Two 
compounds, viz, ZINC01729523 and 
ZINC04692015, show promising results with 
potent inhibition of myocilin, good 
pharmacokinetic properties and absence of toxic 
effects. These molecules can serve as promising 
lead compounds for further structure-based 
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